F
Frank H. Anderson
Researcher at University of British Columbia
Publications - 21
Citations - 3125
Frank H. Anderson is an academic researcher from University of British Columbia. The author has contributed to research in topics: Infliximab & Crohn's disease. The author has an hindex of 13, co-authored 21 publications receiving 2962 citations.
Papers
More filters
Journal ArticleDOI
Infliximab Maintenance Therapy for Fistulizing Crohn's Disease
Bruce E. Sands,Frank H. Anderson,Charles N. Bernstein,William Y. Chey,Brian G. Feagan,Richard N. Fedorak,Michael A. Kamm,Joshua R. Korzenik,Bret A. Lashner,Jane E. Onken,Daniel Rachmilewitz,Paul Rutgeerts,Gary Wild,Douglas C. Wolf,Paul Marsters,Suzanne Travers,Marion Blank,Sander J. H. van Deventer +17 more
TL;DR: Patients with fistulizing Crohn's disease who have a response to induction therapy with inflIXimab have an increased likelihood of a sustained response over a 54-week period if infliximab treatment is continued every 8 weeks.
Journal ArticleDOI
Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection
Ching-Lung Lai,Mohamed Rosmawati,Judy Lao,Hans Van Vlierberghe,Frank H. Anderson,Neal Thomas,Deborah DeHertogh +6 more
TL;DR: This study showed that entecavir has potent antiviral activity against HBV at 0.1- mg/day and 0.5-mg/day doses, both of which were superior to lamivudine in chronically infected HBV patients.
Journal ArticleDOI
Methotrexate in Combination With Infliximab Is No More Effective Than Infliximab Alone in Patients With Crohn's Disease
Brian G. Feagan,John W.D. McDonald,Remo Panaccione,Robert Enns,Charles N. Bernstein,Terry Ponich,Terry Ponich,Raymond Bourdages,Donald G. MacIntosh,Chrystian Dallaire,Albert Cohen,Richard N. Fedorak,Pierre Paré,Alain Bitton,Fred Saibil,Frank H. Anderson,Allan Donner,Cindy J. Wong,Guangyong Zou,Margaret K. Vandervoort,Marybeth Hopkins,Gordon R. Greenberg +21 more
TL;DR: The combination of infliximab and methotrexate, although safe, was no more effective than inflIXimab alone in patients with CD receiving treatment with prednisone.
Journal ArticleDOI
Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial
G Van Assche,William J. Sandborn,Brian G. Feagan,Bruce Salzberg,D Silvers,P S Monroe,William M. Pandak,Frank H. Anderson,John F. Valentine,Gary Wild,D J Geenen,R Sprague,S. R. Targan,Paul Rutgeerts,V Vexler,D Young,R S Shames +16 more
TL;DR: Patients with moderate ulcerative colitis who are treated with daclizumab are not more likely to be in remission or response at eight weeks than patients treated with placebo.
Journal ArticleDOI
Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy
Morris Sherman,Eric M. Yoshida,Marc Deschênes,Mel Krajden,Vincent G. Bain,Kevork M. Peltekian,Frank H. Anderson,Kelly Kaita,Susan Simonyi,Robert Balshaw,S. S. Lee +10 more
TL;DR: These results in a large patient cohort demonstrate that it is possible to cure a proportion of previous non-responders and relapsers by retreating with peginterferon alfa-2a (40KD) plus ribavirin.